8-K current report · filed Aug 6, 2026

Edgewise Therapeutics, Inc. (EWTX) 8-K Current Report: August 6, 2026

Item EX-99.1Item 2.02EWTX overview

Short answer

Edgewise Therapeutics, Inc. (EWTX) filed an 8-K current report with the SEC on August 6, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results announced for quarter ended June 30, 2026.

Edgewise Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 financial results announced for quarter ended June 30, 2026
  • Press release attached as Exhibit 99.1, containing the substantive results and management commentary
  • Investor focus: cash position, operating expenses, clinical spending and development updates disclosed in Exhibit 99.1

Item EX-99.1 · Exhibit EX-99.1

  • Q2 2026 net loss $57.3M, or $0.53 per share, versus $36.1M, or $0.34, in Q2 2025
  • Cash, equivalents and marketable securities $460.7M at June 30; pro forma $2.01B after $1.55B Servier upfront proceeds
  • Servier acquired sevasemten and the muscular dystrophy business for $1.55B upfront plus up to $1.1B milestones
  • Positive 12-week Phase 2 CIRRUS-HCM data supports EDG-7500 Phase 3 initiation expected in Q4 2026
  • R&D expense rose to $47.5M from $33.6M as EDG-7500 and EDG-15400 clinical activity accelerated

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Edgewise Therapeutics, Inc. 8-K filings

Get the next EWTX 8-K as it lands

Follow EWTX for push alerts, or ask the research agent what this filing means.